Senti Biosciences Stock (NASDAQ:SNTI), Trade Ideas

Senti Biosciences

Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.

Biotech

News

Penny Stocks

Health Care

Movers

General

SNTI

Senti Biosciences Inc (NASDAQ: SNTI) received FDA clearance for its Investigational New Drug (IND) application for SENTI-202, an off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3 expressing hemato

Why Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today?

Earnings

Eurozone

Commodities

Small Cap

Global

Intraday Update

Markets

Trading Ideas

ALTO

DDOG

OPRT

TMDX

UBER

VTYX

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 1% on Tuesday

The Dow traded up 0.21% to 34,166.89 while the NASDAQ rose 1.09% to 13,666.65. The S&amp;P 500 also rose, gaining, 0.41% to 4,383.80.

Crude Oil Falls Sharply; Datadog Shares Spike Higher

ADTN

ALPN

AMRC

ATSG

AUGX

AURA

CHRS

CLOV

CNHI

DCGO

EVCM

EVER

FGEN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

ICUI

JWEL

LIFW

MGNX

MYGN

NINE

OLPX

OMIC

OSCR

PLNT

PRAA

PXMD

RMCO

ROVR

SAGE

SANM

SGRY

SNOW

STRL

TASK

TCMD

TDUP

THAR

TRIP

TWKS

VMEO

WLDS

WWAC

Gainers


	PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.


Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Senti Biosciences Inc

Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.28) by 50 percent.

Earnings Misses

Senti Biosciences Q4 2023 GAAP EPS $(0.42) Misses $(0.28) Estimate

<h3>Gainers</h3>
<ul>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) shares rose 11.1% to $0.99 during Tuesday's after-market session. The market value of their outstanding shares is at $19.4 million. </li>
<li>MyMD Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYMD#NASDAQ">MYMD</a>) stock rose 8.14% to $0.2. The company's market cap stands at $9.9 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares increased by 7.29% to $1.47. The company's market cap stands at $4.6 million. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) shares increased by 4.99% to $0.48. The company's market cap stands at $16.0 million. </li>
<li>Connect Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTB#NASDAQ">CNTB</a>) shares moved upwards by 4.83% to $1.3. The company's market cap stands at $71.5 million. </li>
<li>AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) shares moved upwards by 4.65% to $0.45. The company's market cap stands at $21.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Intelligent Bio Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBS#NASDAQ">INBS</a>) stock decreased by 5.1% to $0.29 during Tuesday's after-market session. The company's market cap stands at $2.5 million. </li>
<li>Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) shares fell 4.82% to $2.77. The company's market cap stands at $286.9 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) stock fell 4.81% to $0.42. The company's market cap stands at $18.7 million. </li>
<li>Cue Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLTH#NASDAQ">HLTH</a>) stock decreased by 4.53% to $0.21. The company's market cap stands at $32.6 million. </li>
<li>Aileron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRN#NASDAQ">ALRN</a>) stock decreased by 4.26% to $4.5. The company's market cap stands at $21.9 million. </li>
<li>Silk Road Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILK#NASDAQ">SILK</a>) stock fell 3.91% to $14.26. The company's market cap stands at $555.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALRN

CNTB

ENSC

HLTH

HUMA

Intelligent Bio Solutions Inc. - Common Stock

INBS

MBRX

MyMD Pharmaceuticals, Inc. - Common Stock

MYMD

RDHL

SILK

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) shares rose 23.1% to $1.49 during Monday's pre-market session. The market value of their outstanding shares is at $21.4 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock moved upwards by 19.8% to $0.75. The market value of their outstanding shares is at $4.3 million. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) shares moved upwards by 17.61% to $0.37. The company's market cap stands at $11.1 million. </li>
<li>scPharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCPH#NASDAQ">SCPH</a>) stock increased by 16.47% to $6.22. The company's market cap stands at $223.0 million. </li>
<li>OpGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPGN#NASDAQ">OPGN</a>) shares increased by 16.32% to $0.29. The company's market cap stands at $2.9 million. </li>
<li>Bullfrog AI Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRG#NASDAQ">BFRG</a>) shares rose 15.95% to $5.67. The company's market cap stands at $34.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock declined by 20.9% to $1.5 during Monday's pre-market session. The company's market cap stands at $3.7 million. </li>
<li>XBiotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBIT#NASDAQ">XBIT</a>) shares fell 20.44% to $3.7. The company's market cap stands at $112.6 million. </li>
<li>NexImmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXI#NASDAQ">NEXI</a>) shares declined by 17.86% to $5.75. The market value of their outstanding shares is at $6.0 million. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock declined by 13.3% to $0.91. The company's market cap stands at $7.4 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares decreased by 11.17% to $0.37. The market value of their outstanding shares is at $16.5 million. </li>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares decreased by 9.7% to $0.27. The company's market cap stands at $57.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEMD

BFRG

BNOX

CELU

NEXI

OPGN

SCPH

SXTP

TBIO

XBIT

12 Health Care Stocks Moving In Monday's Pre-Market Session

Senti Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) (&ldquo;Senti Bio&rdquo; or the &ldquo;Company&rdquo;), a clinical stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced plans to streamline its business operations, including reducing its workforce by approximately 37 percent, to enable increased focus on SENTI-202, a first-in-class Logic Gated investigational cell therapy for the treatment of acute myeloid leukemia (&ldquo;AML&rdquo;). The Investigational New Drug (&ldquo;IND&rdquo;) application for SENTI-202 was cleared by the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) in December 2023 and the Company anticipates dosing the first patient in the second quarter of 2024. Additionally, the Company will continue to support the clinical development activities of SENTI-301A for the treatment of advanced glypican 3 (&ldquo;GPC3&rdquo;)-expressing hepatocellular carcinoma (&ldquo;HCC&rdquo;) in China through its partnership with Celest Therapeutics. The Company expects that these resource allocation efforts, combined with other expected receivables, will extend its cash runway into the first quarter of 2025.
&ldquo;We have made significant progress toward our mission to advance our Gene Circuit enhanced oncology cell therapies and recently achieved our milestone of IND clearance for SENTI-202, in line with our previous guidance. Despite this progress, we are taking the difficult but necessary steps to enhance our focus on demonstrating clinical proof-of-concept for our Gene Circuit technology and potentially bringing SENTI-202 and SENTI-301A to patients,&rdquo; said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio. &ldquo;With these resource allocation efforts, our team will remain laser-focused on the clinical progress of SENTI-202 and supporting our partnership with Celest Therapeutics for SENTI-301A in China. We extend our immense gratitude to our dedicated colleagues impacted by this decision and are committed to supporting them throughout this process.&rdquo;

Guidance

Senti Biosciences  Said Reducing Its Workforce By ~37% As Part Of Prioritizing Its Investment In Lead Clinical Program

<h3>Gainers</h3>
<ul>
<li>Karuna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRTX#NASDAQ">KRTX</a>) shares increased by 47.4% to $317.1 during Monday's pre-market session. The company's market cap stands at $11.9 billion. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares rose 30.21% to $1.55. The company's market cap stands at $5.6 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares rose 26.97% to $0.56. The company's market cap stands at $24.8 million. </li>
<li>Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) shares increased by 17.9% to $0.87. The company's market cap stands at $78.6 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) shares increased by 14.14% to $0.51. The company's market cap stands at $19.6 million. </li>
<li>Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) stock moved upwards by 13.45% to $0.51. The market value of their outstanding shares is at $51.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) shares declined by 67.0% to $0.77 during Monday's pre-market session. The company's market cap stands at $87.8 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock declined by 37.5% to $2.25. The market value of their outstanding shares is at $1.8 million. </li>
<li>Castle Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSTL#NASDAQ">CSTL</a>) shares fell 26.58% to $16.0. The market value of their outstanding shares is at $430.5 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock fell 19.55% to $0.89. The market value of their outstanding shares is at $5.1 million. </li>
<li>Nanobiotix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTX#NASDAQ">NBTX</a>) shares fell 13.16% to $6.67. The market value of their outstanding shares is at $314.2 million. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) shares fell 12.39% to $2.83. The market value of their outstanding shares is at $4.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALVR

ATRA

BFRI

CDTX

CSTL

CYCC

KRTX

NBTX

TRIB

WIIM

Senti Biosciences shares are trading higher after the company announced FDA clearance for its IND application for SENTI-202 for the treatment of relapsed or refractory hematologic malignancies including acute myeloid leukemia.

Senti Biosciences Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snti#NASDAQ">SNTI</a>) received FDA clearance for its Investigational New Drug (IND) application for SENTI-202, an off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies while sparing&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/23/12/g36358652/senti-bio-announces-fda-clearance-of-ind-application-for-senti-202-for-the-treatment-of-relapsed-o" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">healthy bone marrow cells</a>.
The company plans to initiate a Phase 1 clinical trial of SENTI-202 in 2024 in multiple sites in the U.S. and Australia and expects to treat the first patient in the second quarter of 2024.&nbsp;
The dose-finding trial will evaluate two dose levels, either 1 or 1.5 billion SENTI-202 cells, administered after lymphodepleting conditioning in adult patients with relapsed or refractory (r/r) CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia (AML).&nbsp;
Initial dosing will consist of three doses administered weekly following lymphodepletion, with the option to receive continuation cycles of lymphodepletion and SENTI-202 cells based on safety and efficacy data.
The company expects to disclose initial efficacy data from the Phase 1 trial by year-end 2024 and durability data in 2025. Through Senti Bio&#39;s previously announced&nbsp;<a class="editor-rtfLink" href="https://www.globenewswire.com/Tracker?data=SRe0dBBfpXuFRhzmCe3riUY7kDlIPxo4DX5ercj9Q6cF-Q_qQX4Hze4II0V1YaDHZdDrA6fPkwgv93chsT1Jbb-VwCf8LRF3axMui5bGCVHGqdLkOJNsIaYqm0SohmblEoN8hGd7oWCJAA4n06L1kZ2w3t99TigV_jYiubmjVopN1_sn2Q8OMAgyYed0_Ul7RPGKGfUn5XBoSdJlgJNoeg==" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">agreement</a>&nbsp;with GeneFab, the company has prepaid the majority of manufacturing-related expenses through the completion of the Phase 1 trial.
Price Action:&nbsp;SNTI shares are up 30.7% at $0.58 on the last check Friday.

<h3>Gainers</h3>
<ul>
<li>Karuna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRTX#NASDAQ">KRTX</a>) stock moved upwards by 47.9% to $318.17 during Friday's pre-market session. The company's market cap stands at $12.0 billion. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) stock moved upwards by 29.29% to $0.57. The market value of their outstanding shares is at $25.2 million. </li>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) stock increased by 23.89% to $0.94. </li>
<li>Galecto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLTO#NASDAQ">GLTO</a>) shares increased by 19.81% to $0.74. The market value of their outstanding shares is at $20.1 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) stock increased by 15.99% to $2.9. The company's market cap stands at $1.9 million. </li>
<li>Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) shares moved upwards by 14.28% to $4.4. The company's market cap stands at $122.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) shares declined by 57.5% to $0.99 during Friday's pre-market session. The market value of their outstanding shares is at $112.9 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock decreased by 14.11% to $0.94. The market value of their outstanding shares is at $5.4 million. </li>
<li>Nanobiotix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTX#NASDAQ">NBTX</a>) stock declined by 12.77% to $6.7. The company's market cap stands at $315.6 million. </li>
<li>DMK Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMK#NASDAQ">DMK</a>) shares decreased by 12.4% to $0.67. The market value of their outstanding shares is at $6.7 million. </li>
<li>Oncternal Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCT#NASDAQ">ONCT</a>) stock decreased by 11.52% to $0.57. The company's market cap stands at $33.3 million. </li>
<li>ThermoGenesis Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>) shares fell 10.76% to $0.52. The company's market cap stands at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GLTO

ONCT

RVPH

SNES

TCBP

THMO

12 Health Care Stocks Moving In Friday's Pre-Market Session

Senti Biosciences Announces FDA Clearance Of IND Application For SENTI-202 For The Treatment Of Relapsed Or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

<h3>Gainers</h3>
<ul>
<li>Jin Medical International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) stock moved upwards by 72.5% to $175.76 during Monday's after-market session. The market value of their outstanding shares is at $1.3 billion. </li>
<li>Panbela Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBLA#NASDAQ">PBLA</a>) shares rose 18.81% to $1.2. The company's market cap stands at $6.1 million. </li>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) shares increased by 8.14% to $1.46. The market value of their outstanding shares is at $63.1 million. </li>
<li>Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) stock increased by 7.58% to $3.83. The company's market cap stands at $106.9 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares moved upwards by 7.51% to $1.43. The market value of their outstanding shares is at $8.8 million. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) stock rose 6.55% to $0.39. The company's market cap stands at $2.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) shares decreased by 12.1% to $0.37 during Monday's after-market session. The market value of their outstanding shares is at $31.5 million. </li>
<li>bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) stock declined by 11.48% to $2.7. The market value of their outstanding shares is at $295.2 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares decreased by 8.46% to $0.38. The company's market cap stands at $16.9 million. </li>
<li>Motus GI Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOTS#NASDAQ">MOTS</a>) stock declined by 7.91% to $1.98. The market value of their outstanding shares is at $1.3 million. </li>
<li>Zura Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZURA#NASDAQ">ZURA</a>) shares decreased by 7.68% to $4.45. The market value of their outstanding shares is at $191.7 million. </li>
<li>BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) shares fell 6.3% to $1.86. The company's market cap stands at $89.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCAB

BLUE

CNSP

INAB

MOTS

NRXP

PBLA

ZJYL

ZURA

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares rose 58.2% to $0.4 during Tuesday's after-market session. The company's market cap stands at $5.2 million. </li>
<li>NightHawk Biosciences (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NHWK#AMEX">NHWK</a>) shares moved upwards by 12.9% to $0.35. The company's market cap stands at $9.1 million. </li>
<li>Minerva Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTRS#NASDAQ">UTRS</a>) shares rose 9.99% to $2.42. The company's market cap stands at $21.4 million. </li>
<li>Yield10 Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) shares moved upwards by 9.5% to $0.22. The market value of their outstanding shares is at $2.6 million. </li>
<li>Inhibikase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) stock moved upwards by 8.33% to $1.3. The company's market cap stands at $8.0 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) stock rose 8.31% to $0.38. The market value of their outstanding shares is at $16.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>LumiraDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMDX#NASDAQ">LMDX</a>) stock decreased by 7.7% to $0.11 during Tuesday's after-market session. The company's market cap stands at $36.6 million. </li>
<li>Fate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) shares declined by 6.67% to $2.24. The company's market cap stands at $220.8 million. </li>
<li>Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) shares declined by 5.51% to $4.46. The market value of their outstanding shares is at $139.7 million. </li>
<li>Gracell Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRCL#NASDAQ">GRCL</a>) shares fell 5.0% to $5.14. The market value of their outstanding shares is at $493.0 million. </li>
<li>First Wave BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWBI#NASDAQ">FWBI</a>) stock fell 4.84% to $0.29. The company's market cap stands at $3.9 million. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) stock decreased by 4.82% to $3.76. The company's market cap stands at $16.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FATE

FWBI

GRCL

HEPA

LMDX

NHWK

RSLS

SERA

UTRS

YTEN

<h3>Gainers</h3>
<ul>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) stock rose 54.5% to $0.66 during Thursday's after-market session. The market value of their outstanding shares is at $5.7 million. </li>
<li>Aligos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGS#NASDAQ">ALGS</a>) stock moved upwards by 33.84% to $0.87. The market value of their outstanding shares is at $65.1 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) stock rose 7.86% to $0.41. The market value of their outstanding shares is at $9.7 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock rose 7.31% to $0.28. The company's market cap stands at $3.6 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock moved upwards by 7.26% to $0.65. The market value of their outstanding shares is at $1.6 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock increased by 6.34% to $2.18. The market value of their outstanding shares is at $2.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Avid Bioservices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDMO#NASDAQ">CDMO</a>) shares decreased by 22.5% to $4.1 during Thursday's after-market session. The market value of their outstanding shares is at $258.7 million. The company's, Q2 earnings came out today. </li>
<li>Processa Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) stock decreased by 9.53% to $0.73. The company's market cap stands at $18.0 million. </li>
<li>Solid Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) stock declined by 8.69% to $5.26. The market value of their outstanding shares is at $106.1 million. </li>
<li>Modular Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODD#NASDAQ">MODD</a>) shares decreased by 7.6% to $1.46. The market value of their outstanding shares is at $30.9 million. </li>
<li>89bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETNB#NASDAQ">ETNB</a>) stock fell 7.04% to $9.25. The company's market cap stands at $699.6 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares declined by 6.87% to $0.39. The market value of their outstanding shares is at $17.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADIL

ALGS

CDMO

ETNB

MODD

PCSA

SLDB

TNXP

XCUR

12 Health Care Stocks Moving In Thursday's After-Market Session

Senti Biosciences Q3 2023 EPS $(0.34) Up From $(0.38) YoY, Revenue $338K

<h3>Gainers</h3>
<ul>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock moved upwards by 15.8% to $0.54 during Monday's after-market session. This security traded at a volume of 1.4 million shares come close, making up 1011.8% of its average volume over the last 100 days. The company's market cap stands at $3.2 million. </li>
<li>Kronos Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRON#NASDAQ">KRON</a>) stock rose 8.33% to $0.81. The company's market cap stands at $47.3 million. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) shares increased by 7.08% to $0.33. The market value of their outstanding shares is at $4.7 million. The company's, Q3 earnings came out 2 days ago. </li>
<li>Azenta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZTA#NASDAQ">AZTA</a>) shares increased by 6.67% to $51.0. Azenta's trading volume hit 76.4K shares by close, accounting for 10.8% of its average volume over the last 100 days. The market value of their outstanding shares is at $3.0 billion. The company's, Q4 earnings came out today. </li>
<li>PaxMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXMD#NASDAQ">PXMD</a>) shares increased by 6.43% to $1.82. This security traded at a volume of 58.1K shares come close, making up 8.1% of its average volume over the last 100 days. The market value of their outstanding shares is at $1.8 million. </li>
<li>Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) stock increased by 6.3% to $1.18. The market value of their outstanding shares is at $62.2 million. As per the news, the Q3 earnings report came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Harrow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) shares decreased by 23.9% to $9.76 during Monday's after-market session. This security traded at a volume of 164.8K shares come close, making up 31.8% of its average volume over the last 100 days. The company's market cap stands at $342.7 million. As per the press release, Q3 earnings came out today. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares declined by 13.8% to $1.75. Today's trading volume for this security ended up closing at 67.1K shares, which is 19.7 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $55.4 million. As per the press release, Q2 earnings came out today. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares fell 12.45% to $0.38. This security traded at a volume of 158.6K shares come close, making up 6.6% of its average volume over the last 100 days. The company's market cap stands at $16.9 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares declined by 9.8% to $0.5. The market value of their outstanding shares is at $5.9 million. </li>
<li>Owlet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWLT#NYSE">OWLT</a>) stock declined by 9.48% to $5.83. The market value of their outstanding shares is at $49.4 million. The company's, Q3 earnings came out today. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) shares decreased by 8.22% to $3.13. The company's market cap stands at $13.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATNF

AZTA

HROW

KRON

MNPR

OWLT

SPRO

XAIR

<h3>Gainers</h3>
<ul>
<li>Heart Test Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) shares moved upwards by 60.5% to $0.24 during Wednesday's regular session. Heart Test Laboratories's stock is trading at a volume of 74.2 million shares as of 12:30 EST. This is 43154.1% of its average full-day volume over the last 100 days. The company's market cap stands at $2.6 million. </li>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) stock increased by 43.46% to $3.4. Trading volume for this security as of 12:30 EST is 13.7 million, which is 977.2% of its average full-day volume over the last 100 days. The company's market cap stands at $7.6 million. </li>
<li>Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) shares rose 28.82% to $1.24. Trading volume for Personalis's stock is 1.2 million as of 12:30 EST. This is 652.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $60.1 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Cyclo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTH#NASDAQ">CYTH</a>) stock moved upwards by 20.61% to $1.58. As of 12:30 EST, Cyclo Therapeutics's stock is trading at a volume of 389.9K, which is 859.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $30.5 million. </li>
<li>Viracta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRX#NASDAQ">VIRX</a>) stock increased by 17.99% to $0.8. Trading volume for this security as of 12:30 EST is 132.5K, which is 167.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $30.8 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) stock moved upwards by 17.28% to $0.61. Trading volume for this security as of 12:30 EST is 16.7 million, which is 960.4% of its average full-day volume over the last 100 days. The company's market cap stands at $27.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) stock decreased by 76.4% to $0.61 during Wednesday's regular session. Trading volume for this security as of 12:30 EST is 10.6 million, which is 3563.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $16.7 million. </li>
<li>Establishment Labs Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESTA#NASDAQ">ESTA</a>) stock decreased by 38.71% to $20.04. As of 12:30 EST, this security is trading at a volume of 3.5 million shares, making up 1535.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $516.5 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Maravai LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) stock declined by 27.04% to $5.02. Trading volume for this security as of 12:30 EST is 3.7 million, which is 152.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $662.2 million. The company's, Q3 earnings came out yesterday. </li>
<li>Panbela Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBLA#NASDAQ">PBLA</a>) shares declined by 26.28% to $0.7. The current volume of 368.7K shares is 36.5% of Panbela Therapeutics's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $2.0 million. </li>
<li>PaxMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXMD#NASDAQ">PXMD</a>) shares fell 23.61% to $3.44. The current volume of 885.3K shares is 132.0% of PaxMedica's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $3.4 million. </li>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) stock decreased by 22.14% to $0.95. Ontrak's stock is trading at a volume of 51.6K shares as of 12:30 EST. This is 115.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $4.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CYTH

DRRX

ESTA

HSCS

MRVI

OTRK

PSNL

TNON

VIRX

12 Health Care Stocks Moving In Wednesday's Intraday Session

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 1% on Tuesday
The Dow traded up 0.21% to 34,166.89 while the NASDAQ rose 1.09% to 13,666.65. The S&amp;P 500 also rose, gaining, 0.41% to 4,383.80.
Check This Out: <a href="https://www.benzinga.com/news/23/11/35641683/top-4-industrial-stocks-that-could-sink-your-portfolio-in-november"> Top 4 Industrial Stocks That Could Sink Your Portfolio In November</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Information technology shares jumped by 1.2% on Tuesday.
In trading on Tuesday, energy shares fell by 2.2%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
Uber Technologies, Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uber#NYSE">UBER</a>) reported an increase in sales for the third quarter.
The company&rsquo;s third-quarter revenue increased 11% year-over-year to $9.29 billion, missing the consensus of $9.52 billion. Uber&#39;s GAAP EPS of $0.10 missed the consensus of $0.12.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
TransMedics Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) shares shot up 54% to $61.95 after the company reported better-than-expected third-quarter sales results and issued strong FY23 revenue guidance.
Shares of Senti Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snti#NASDAQ">SNTI</a>) got a boost, shooting 87% to $0.5462 after the company reported a new strategic collaboration with Celest Therapeutics for the clinical development of SENTI-301A in China.
Datadog, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ddog#NASDAQ">DDOG</a>) shares were also up, gaining 30% to $103.19 after the company reported better-than-expected third-quarter results and issued strong guidance.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Ventyx Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtyx#NASDAQ">VTYX</a>) shares dropped 82% to $2.5889 after the company announced efficacy results from the Phase 2 trial of VTX958 in plaque psoriasis did not meet the internal target to support further development of VTX958 in psoriasis.
Shares of Alto Ingredients, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alto#NASDAQ">ALTO</a>) were down 59% to $2.0050 after the company reported mixed third-quarter financial results.
Oportun Financial Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/oprt#NASDAQ">OPRT</a>) was down, falling 48% to $3.0450 after reporting a loss for the third quarter.
Also Check This Out:<a href="https://www.benzinga.com/trading-ideas/long-ideas/23/11/35636701/jim-cramer-says-this-tech-company-reported-a-dynamite-quarter-i-disliked-these-guys-for-"> Jim Cramer Says This Tech Company Reported A &#39;Dynamite&#39; Quarter: &#39;I Disliked These Guys For A Long Time, Not Anymore&#39;</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 4.2% to $77.45 while gold traded down 0.9% at $1,970.80.
Silver traded down 2.9% to $22.565 on Tuesday while copper fell 1.1% to $3.6795.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares closed mostly lower today. The eurozone&rsquo;s STOXX 600 fell 0.16%, London&rsquo;s FTSE 100 fell 0.10% while Spain&rsquo;s IBEX 35 Index fell 0.06% The German DAX gained 0.11% French CAC 40 fell 0.39%, while Italy&rsquo;s FTSE MIB Index fell 0.69%.
Industrial producer prices in the Eurozone declined by 12.4% year-over-year in September versus an 11.5% decline a month ago, while the HCOB construction PMI declined to 42.7 in October from 43.6 in September.
The S&amp;P Global France construction PMI declined to 41 in October from 43.7 in September, while German construction PMI fell to 38.3 in October, recording the lowest reading since April 2020. Industrial production in Germany fell 1.4% month-over-month for September, while UK&rsquo;s Halifax House Price Index fell by 3.2% year-over-year in October.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed lower on Tuesday, with Japan&rsquo;s Nikkei 225 falling 1.34%, Hong Kong&rsquo;s Hang Seng Index declining 1.65% and China&rsquo;s Shanghai Composite Index falling 0.04%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, fell around 0.03%.
China&#39;s trade surplus in October 2023 narrowed to $56.53 billion from $82.35 billion in the year-ago-month. Chinese foreign exchange reserves fell to $3.101 trillion in October from the previous month&#39;s reading of $3.115 trillion, while foreign exchange reserves in Hong Kong increased to $416 billion in October.
&nbsp;
<h3>Economics</h3>
&nbsp;
The Logistics Manager&rsquo;s Index in the U.S. rose to 56.5 in October versus 52.4 in the prior month.
The Manheim Used Vehicle Value Index fell 2.3% month-over-month for October.
The trade deficit in the U.S. increased to $61.5 billion in September versus a revised $58.7 billion gap in the prior month and compared to market estimates of $59.9 billion.
Now Read This: <a href="https://www.benzinga.com/news/23/11/35641526/insiders-selling-amazon-costco-and-2-other-stocks"> Insiders Selling Amazon, Costco And 2 Other Stocks</a>

<h3>Gainers</h3>
<ul>
<li>PaxMedica, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pxmd#NASDAQ">PXMD</a>) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.</li>
<li>Senti Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snti#NASDAQ">SNTI</a>) gained 83% to $0.5298 after the company reported a new strategic collaboration with Celest Therapeutics for the clinical development of SENTI-301A in China. Senti is eligible to receive up to $156 million in milestones and royalties.</li>
<li>Tharimmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/thar#NASDAQ">THAR</a>) shares climbed 57.8% to $0.2488 as the company disclosed the execution of an exclusive worldwide licensing agreement with Avior Inc. d/b/a Avior Bio, LLC to develop, market and commercialize a clinical-stage asset, AV104.</li>
<li>TransMedics Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) shares gained 56.7% to $63.03 after the company reported better-than-expected third-quarter sales results and issued strong FY23 revenue guidance.</li>
<li>Singular Genomics Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/omic#NASDAQ">OMIC</a>) rose 39.1% to $0.5350.</li>
<li>Olaplex Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/olpx#NASDAQ">OLPX</a>) gained 39% to $1.92 following strong quarterly results.</li>
<li>Datadog, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ddog#NASDAQ">DDOG</a>) climbed 28.6% to $102.28 after the company reported better-than-expected third-quarter results and issued strong guidance.</li>
<li>Augmedix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/augx#NASDAQ">AUGX</a>) shares rose 24% to $5.64 following strong third-quarter results.</li>
<li>Rover Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rovr#NASDAQ">ROVR</a>) gained 23.7% to $7.99 following upbeat results. The company&rsquo;s board also approved extension of share repurchase program with additional $100 million.</li>
<li>MacroGenics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgnx#NASDAQ">MGNX</a>) rose 20.6% to $6.57 after posting a profit for the third quarter.</li>
<li>Jowell Global Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jwel#NASDAQ">JWEL</a>) climbed 18% to $1.96.</li>
<li>Triumph Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tgi#NYSE">TGI</a>) rose 17.6% to $9.30 following strong quarterly results.</li>
<li>Alteryx, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ayx#NYSE">AYX</a>) shares jumped 17.3% to $35.74 after the company reported better-than-expected third-quarter financial results.</li>
<li>Unisys Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uis#NYSE">UIS</a>) shares jumped 16.7% to $3.3780 after the company posted upbeat third-quarter results and raised FY23 revenue growth forecast.</li>
<li>Thoughtworks Holding, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/twks#NASDAQ">TWKS</a>) rose 16.2% to $4.2050 after the company posted upbeat third-quarter results.</li>
<li>TaskUs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/task#NASDAQ">TASK</a>) gained 16% to $11.90 after the company reported better-than-expected third-quarter financial results and issued FY23 revenue guidance above estimates.</li>
<li>Myriad Genetics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mygn#NASDAQ">MYGN</a>) rose 15.8% to $18.92 after the company posted upbeat third-quarter results.</li>
<li>Planet Fitness, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/plnt#NYSE">PLNT</a>) climbed 15.8% to $63.92 after the company reported better-than-expected third-quarter financial results and raised FY23 revenue growth guidance.</li>
<li>EverQuote, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ever#NASDAQ">EVER</a>) gained 15.8% to $8.62 following strong sales.</li>
<li>Oscar Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/oscr#NYSE">OSCR</a>) climbed 14.3% to $6.53 following strong results.</li>
<li>Hims &amp; Hers Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hims#NYSE">HIMS</a>) rose 13.9% to $7.16 after the company reported better-than-expected third-quarter sales results, raised FY23 guidance above estimates and announced a $50 million share repurchase program.</li>
<li>Surgery Partners, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgry#NASDAQ">SGRY</a>) rose 13.2% to $28.08 following upbeat results.</li>
<li>Vimeo, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vmeo#NASDAQ">VMEO</a>) gained 13.2% to $3.7950 following upbeat results.</li>
<li>MongoDB, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdb#NASDAQ">MDB</a>) climbed 12.7% to $374.62.</li>
<li>PRA Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/praa#NASDAQ">PRAA</a>) climbed 11.3% to $16.12 following better-than-expected results.</li>
<li>Snowflake Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/snow#NYSE">SNOW</a>) rose 10.9% to $159.93 in sympathy with Datadog, which reported better-than-expected Q3 results and issued strong guidance.</li>
<li>DocGo Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dcgo#NASDAQ">DCGO</a>) gained 10.2% to $6.39 following strong sales.</li>
<li>Wearable Devices Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wlds#NASDAQ">WLDS</a>) surged 9.7% to $0.8006.</li>
<li>GSE Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gvp#NASDAQ">GVP</a>) rose 9.6% to $3.5961. GSE Solutions was recently awarded a $4.2 million contract from a large utility for nuclear power plant engineering work.</li>
<li>FibroGen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fgen#NASDAQ">FGEN</a>) gained 8.4% to $0.6062 following upbeat results.</li>
<li>Tripadvisor, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trip#NASDAQ">TRIP</a>) shares rose 4.8% to $16.89 after the company reported better-than-expected third-quarter financial results.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ventyx Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtyx#NASDAQ">VTYX</a>) shares fell 80.8% to $2.71 after the company announced efficacy results from the Phase 2 trial of VTX958 in plaque psoriasis did not meet the internal target to support further development of VTX958 in psoriasis.</li>
<li>Alto Ingredients, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alto#NASDAQ">ALTO</a>) fell 58.1% to $2.0594 after the company reported mixed third-quarter financial results.</li>
<li>Worldwide Webb Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wwac#NASDAQ">WWAC</a>) fell 51% to $3.56.</li>
<li>Oportun Financial Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/oprt#NASDAQ">OPRT</a>) fell 47% to $3.08 after reporting a loss for the third quarter.</li>
<li>Royalty Management Holding Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rmco#NASDAQ">RMCO</a>) dipped 41.6% to $5.80.</li>
<li>Aura Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aura#NASDAQ">AURA</a>) fell 33% to $7.37. Aura Biosciences priced its public offering of 11 million common shares at $9 per share.</li>
<li>ThredUp Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tdup#NASDAQ">TDUP</a>) fell 30.5% to $2.3901 following weak results.</li>
<li>ADTRAN Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adtn#NASDAQ">ADTN</a>) shares fell 28% to $5.28 following a wider-than-expected quarterly loss.</li>
<li>Olo Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/olo#NYSE">OLO</a>) fell 27% to $4.2650 following third-quarter results.</li>
<li>Ameresco, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amrc#NASDAQ">AMRC</a>) shares declined 27% to $19.42 following downbeat third-quarter results.</li>
<li>Air Transport Services Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atsg#NASDAQ">ATSG</a>) dropped 24.4% to $15.29. Air Transport Services reported weaker-than-expected results for its third quarter. The company also named Joe Hete, current Chairman of the Board and its former longtime CEO, as its CEO, effective immediately.</li>
<li>MSP Recovery, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lifw#NASDAQ">LIFW</a>) shares fell 24.2% to $7.32 after jumping 252% on Monday.</li>
<li>Coherus BioSciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chrs#NASDAQ">CHRS</a>) shares fell 23.2% to $2.72 after the company reported mixed third-quarter financial results.</li>
<li>Clover Health Investments, Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clov#NASDAQ">CLOV</a>) shares fell 20.1% to $0.8966 following weak quarterly sales.</li>
<li>Nine Energy Service, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nine#NYSE">NINE</a>) fell 19.4% to $2.7631 following downbeat sales.</li>
<li>Tactile Systems Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcmd#NASDAQ">TCMD</a>) fell 17.2% to $10.46 following quarterly results.</li>
<li>Sterling Infrastructure, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/strl#NASDAQ">STRL</a>) declined 16.3% to $62.42 following weak sales.</li>
<li>ICU Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icui#NASDAQ">ICUI</a>) fell 16.3% to $85.34 following downbeat sales.</li>
<li>EverCommerce Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evcm#NASDAQ">EVCM</a>) dipped 15% to $8.16 following weak sales.</li>
<li>Sanmina Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sanm#NASDAQ">SANM</a>) shares fell 14.5% to $45.15 after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Alpine Immune Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alpn#NASDAQ">ALPN</a>) fell 11.4% to $12.49. Alpine Immune Sciences priced its $150 million public offering of 8.8 million common shares at $12.50 per share.</li>
<li>CNH Industrial N.V. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cnhi#NYSE">CNHI</a>) fell 8.6% to $10.36 after the company reported mixed third-quarter financial results and issued guidance.</li>
<li>Sage Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sage#NASDAQ">SAGE</a>) declined 7.4% to $19.09 following third-quarter results.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/23/11/35645492/ethereum-falls-below-this-key-level-neo-becomes-top-loser"> Ethereum Falls Below This Key Level; Neo Becomes Top Loser</a>

Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>PaxMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXMD#NASDAQ">PXMD</a>) stock moved upwards by 84.4% to $5.62 during Tuesday's regular session. As of 12:31 EST, this security is trading at a volume of 29.1 million shares, making up 21158.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $5.6 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) stock rose 78.97% to $0.52. As of 12:31 EST, this security is trading at a volume of 67.9 million shares, making up 13314.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $23.2 million. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) shares moved upwards by 66.17% to $1.13. Cardio Diagnostics Hldgs's stock is trading at a volume of 84.0 million shares as of 12:31 EST. This is 1640.7% of its average full-day volume over the last 100 days. The company's market cap stands at $21.1 million. </li>
<li>TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) shares moved upwards by 53.47% to $61.68. As of 12:31 EST, this security is trading at a volume of 5.5 million shares, making up 659.4% of its average full-day volume over the last 100 days. The company's market cap stands at $2.0 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Korro Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>) shares rose 38.17% to $21.39. Korro Bio's stock is trading at a volume of 131.2K shares as of 12:31 EST. This is 480.7% of its average full-day volume over the last 100 days. The company's market cap stands at $171.1 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock increased by 34.11% to $0.21. Trading volume for this security as of 12:31 EST is 40.0 million, which is 2014.8% of its average full-day volume over the last 100 days. The company's market cap stands at $3.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ventyx Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTYX#NASDAQ">VTYX</a>) stock decreased by 80.6% to $2.74 during Tuesday's regular session. As of 12:31 EST, Ventyx Biosciences's stock is trading at a volume of 28.0 million, which is 3501.0% of its average full-day volume over the last 100 days. The company's market cap stands at $161.3 million. </li>
<li>Aura Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AURA#NASDAQ">AURA</a>) shares decreased by 41.9% to $6.39. The current volume of 1.9 million shares is 3151.9% of Aura Biosciences's average full-day volume over the last 100 days (last updated at 12:31 EST). The market value of their outstanding shares is at $244.1 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) stock fell 34.49% to $6.32. Trading volume for MSP Recovery's stock is 9.4 million as of 12:31 EST. This is 304.1% of its average full-day volume over the last 100 days. The company's market cap stands at $84.7 million. </li>
<li>Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) shares fell 28.68% to $2.52. The current volume of 6.4 million shares is 200.9% of Coherus BioSciences's average full-day volume over the last 100 days (last updated at 12:31 EST). The market value of their outstanding shares is at $268.6 million. The company's, Q3 earnings came out yesterday. </li>
<li>Clover Health Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) stock decreased by 21.83% to $0.88. Trading volume for this security as of 12:31 EST is 27.0 million, which is 685.2% of its average full-day volume over the last 100 days. The company's market cap stands at $428.3 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Tactile Systems Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) stock decreased by 20.84% to $10.0. As of 12:31 EST, this security is trading at a volume of 893.9K shares, making up 235.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $234.5 million. As per the news, the Q3 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

KRRO

12 Health Care Stocks Moving In Tuesday's Intraday Session

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Tuesday
The Dow traded up 0.19% to 34,159.14 while the NASDAQ rose 0.84% to 13,631.99. The S&amp;P 500 also rose, gaining, 0.30% to 4,379.06.
Check This Out: <a href="https://www.benzinga.com/news/23/11/35641683/top-4-industrial-stocks-that-could-sink-your-portfolio-in-november"> Top 4 Industrial Stocks That Could Sink Your Portfolio In November</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Information technology shares jumped by 1% on Tuesday.
In trading on Tuesday, energy shares fell by 2.2%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
The trade deficit in the U.S. increased to $61.5 billion in September versus a revised $58.7 billion gap in the prior month and compared to market estimates of $59.9 billion.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
TransMedics Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) shares shot up 62% to $65.22 after the company reported better-than-expected third-quarter sales results and issued strong FY23 revenue guidance.
Shares of Senti Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snti#NASDAQ">SNTI</a>) got a boost, shooting 70% to $0.4974 after the company reported a new strategic collaboration with Celest Therapeutics for the clinical development of SENTI-301A in China.
Tharimmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/thar#NASDAQ">THAR</a>) shares were also up, gaining 49% to $0.2350 as the company disclosed the execution of an exclusive worldwide licensing agreement with Avior Inc. d/b/a Avior Bio, LLC to develop, market and commercialize a clinical-stage asset, AV104.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Ventyx Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtyx#NASDAQ">VTYX</a>) shares dropped 81% to $2.64 after the company announced efficacy results from the Phase 2 trial of VTX958 in plaque psoriasis did not meet the internal target to support further development of VTX958 in psoriasis.
Shares of Alto Ingredients, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alto#NASDAQ">ALTO</a>) were down 58% to $2.04 after the company reported mixed third-quarter financial results.
Oportun Financial Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/oprt#NASDAQ">OPRT</a>) was down, falling 45% to $3.22 after reporting a loss for the third quarter.
Also Check This Out:<a href="https://www.benzinga.com/trading-ideas/long-ideas/23/11/35636701/jim-cramer-says-this-tech-company-reported-a-dynamite-quarter-i-disliked-these-guys-for-"> Jim Cramer Says This Tech Company Reported A &#39;Dynamite&#39; Quarter: &#39;I Disliked These Guys For A Long Time, Not Anymore&#39;</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 3% to $78.38 while gold traded down 0.9% at $1,971.00.
Silver traded down 2.8% to $22.58 on Tuesday while copper fell 1.8% to $3.6530.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mostly lower today. The eurozone&rsquo;s STOXX 600 fell 0.15%, London&rsquo;s FTSE 100 fell 0.13% while Spain&rsquo;s IBEX 35 Index fell 0.18% The German DAX gained 0.05% French CAC 40 fell 0.38%, while Italy&rsquo;s FTSE MIB Index fell 0.59%.
Industrial producer prices in the Eurozone declined by 12.4% year-over-year in September versus an 11.5% decline a month ago, while the HCOB construction PMI declined to 42.7 in October from 43.6 in September.
The S&amp;P Global France construction PMI declined to 41 in October from 43.7 in September, while German construction PMI fell to 38.3 in October, recording the lowest reading since April 2020. Industrial production in Germany fell 1.4% month-over-month for September, while UK&rsquo;s Halifax House Price Index fell by 3.2% year-over-year in October.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed lower on Tuesday, with Japan&rsquo;s Nikkei 225 falling 1.34%, Hong Kong&rsquo;s Hang Seng Index declining 1.65% and China&rsquo;s Shanghai Composite Index falling 0.04%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, fell around 0.03%.
China&#39;s trade surplus in October 2023 narrowed to $56.53 billion from $82.35 billion in the year-ago-month. Chinese foreign exchange reserves fell to $3.101 trillion in October from the previous month&#39;s reading of $3.115 trillion, while foreign exchange reserves in Hong Kong increased to $416 billion in October.
&nbsp;
<h3>Economics</h3>
&nbsp;
The Logistics Manager&rsquo;s Index in the U.S. rose to 56.5 in October versus 52.4 in the prior month.
The Manheim Used Vehicle Value Index fell 2.3% month-over-month for October.
The trade deficit in the U.S. increased to $61.5 billion in September versus a revised $58.7 billion gap in the prior month and compared to market estimates of $59.9 billion.
Now Read This: <a href="https://www.benzinga.com/news/23/11/35641526/insiders-selling-amazon-costco-and-2-other-stocks"> Insiders Selling Amazon, Costco And 2 Other Stocks</a>
&nbsp;

Nasdaq Jumps 100 Points; US Trade Deficit Widens In September

U.S. stocks traded mixed this morning, with the Dow Jones falling around 50 points on Tuesday
Following the market opening Tuesday, the Dow traded down 0.18% to 34,035.79 while the NASDAQ rose 0.14% to 13,537.65. The S&amp;P 500 also fell, dropping, 0.22% to 4,356.26.
Check This Out: <a href="https://www.benzinga.com/news/23/11/35641683/top-4-industrial-stocks-that-could-sink-your-portfolio-in-november"> Top 4 Industrial Stocks That Could Sink Your Portfolio In November</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Information technology shares rose by 0.2% on Tuesday.
In trading on Tuesday, energy shares fell by 2.1%.

Top Headline

D.R. Horton, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dhi#NYSE">DHI</a>) reported better-than-expected earnings for its fourth quarter on Tuesday.
D.R. Horton posted quarterly earnings of $4.45 per share, topping market estimates of $3.93 per share. The company&rsquo;s quarterly sales came in at $10.50 billion versus expectations of $10.01 billion.
D.R. Horton said it sees FY24 consolidated revenues of approximately $36 billion to $37 billion, versus estimates of $36.20 billion.
&nbsp;
Equities Trading UP
PaxMedica, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pxmd#NASDAQ">PXMD</a>) shares shot up 117% to $6.62. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.
Shares of Senti Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snti#NASDAQ">SNTI</a>) got a boost, shooting 86% to $0.5442 after the company reported a new strategic collaboration with Celest Therapeutics for the clinical development of SENTI-301A in China. Senti is eligible to receive up to $156 million in milestones and royalties.
Tharimmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/thar#NASDAQ">THAR</a>) shares were also up, gaining 50% to $0.2360 as the company disclosed the execution of an exclusive worldwide licensing agreement with Avior Inc. d/b/a Avior Bio, LLC to develop, market and commercialize a clinical-stage asset, AV104.

Equities Trading DOWN
Ventyx Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtyx#NASDAQ">VTYX</a>) shares dropped 82% to $2.5201 after the company announced efficacy results from the Phase 2 trial of VTX958 in plaque psoriasis did not meet the internal target to support further development of VTX958 in psoriasis.
Shares of Alto Ingredients, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alto#NASDAQ">ALTO</a>) were down 56% to $2.18 after the company reported mixed third-quarter financial results.
Worldwide Webb Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wwac#NASDAQ">WWAC</a>) was down, falling 40% to $4.43.
Also Check This Out:<a href="https://www.benzinga.com/trading-ideas/long-ideas/23/11/35636701/jim-cramer-says-this-tech-company-reported-a-dynamite-quarter-i-disliked-these-guys-for-"> Jim Cramer Says This Tech Company Reported A &#39;Dynamite&#39; Quarter: &#39;I Disliked These Guys For A Long Time, Not Anymore&#39; </a>

Commodities
In commodity news, oil traded down 1.8% to $79.36 while gold traded down 0.9% at $1,971.70.
Silver traded down 2.5% to $22.645 on Tuesday while copper fell 1.4% to $3.6665.

Euro zone

European shares were mostly lower today. The eurozone&rsquo;s STOXX 600 fell 0.2%, London&rsquo;s FTSE 100 rose 0.1% while Spain&rsquo;s IBEX 35 Index fell 0.2% The German DAX fell 0.3% French CAC 40 fell 0.5%, while Italy&rsquo;s FTSE MIB Index fell 0.1%.
Industrial producer prices in the Eurozone declined by 12.4% year-over-year in September versus an 11.5% decline a month ago, while the HCOB construction PMI declined to 42.7 in October from 43.6 in September.
The S&amp;P Global France construction PMI declined to 41 in October from 43.7 in September, while German construction PMI fell to 38.3 in October, recording the lowest reading since April 2020. Industrial production in Germany fell 1.4% month-over-month for September, while UK&rsquo;s Halifax House Price Index fell by 3.2% year-over-year in October.
&nbsp;
Asia Pacific Markets

Asian markets closed lower on Tuesday, with Japan&rsquo;s Nikkei 225 falling 1.34%, Hong Kong&rsquo;s Hang Seng Index declining 1.65% and China&rsquo;s Shanghai Composite Index falling 0.04%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, fell around 0.03%.
China&#39;s trade surplus in October 2023 narrowed to $56.53 billion from $82.35 billion in the year-ago-month. Chinese foreign exchange reserves fell to $3.101 trillion in October from the previous month&#39;s reading of $3.115 trillion, while foreign exchange reserves in Hong Kong increased to $416 billion in October.

Economics

The Logistics Manager&rsquo;s Index in the U.S. rose to 56.5 in October versus 52.4 in the prior month.
The Manheim Used Vehicle Value Index fell 2.3% month-over-month for October.
The trade deficit in the U.S. increased to $61.5 billion in September versus a revised $58.7 billion gap in the prior month and compared to market estimates of $59.9 billion.
Now Read This: <a href="https://www.benzinga.com/news/23/11/35641526/insiders-selling-amazon-costco-and-2-other-stocks"> Insiders Selling Amazon, Costco And 2 Other Stocks</a>

US Stocks Mixed; D.R. Horton Earnings Top Views

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Ventyx Biosciences&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/vtyx-stock-quote/">VTYX</a>) stock is falling hard on Tuesday after the clinical-stage biopharmaceutical company <a href="https://finance.yahoo.com/news/ventyx-biosciences-announces-results-phase-210100036.html">released poor study results</a>.



These results come from a Phase 2 clinical trial of VTX958 in patients suffering from moderate to severe plaque psoriasis. The bad news here is that the company is stopping the development of the treatment following lackluster trial results.



Ventyx Biosciences notes that VTX958 was successful in meeting its primary and secondary endpoints. However, the efficacy was below the expected levels. Considering the competitive nature of the field the drug was developed for, these results don&rsquo;t warrant the continued development of VTX958 for psoriasis and psoriatic arthritis.



<h2>VTYX Stock Movement Today</h2>



With news of it dropping development of VTX958, shares of Ventyx Biosciences stock are seeing heavy trading on Tuesday. That has some 3.3 million shares changing hands as investors sell the stock. To put that number in perspective, the company&rsquo;s daily average trading volume is about 761,000 shares.



VTYX stock is down 75.8% as of Tuesday morning and was down 52.3% year-to-date when markets closed on Monday.



Investors seeking out even more of the most recent stock market stories are in the right place!



We&rsquo;re offering up insight into all of the hottest stock market news that traders need to know about on Tuesday! A few examples of that include what&rsquo;s going on with shares of Tharimmune&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/thar-stock-quote/">THAR</a>) and Senti Biosciences&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/snti-stock-quote/">SNTI</a>) stock today, as well as the biggest pre-market stock movers this morning. All of these topics are covered in the links below!



<h2>More Tuesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2023/11/why-is-tharimmune-thar-stock-up-113-today/">Why Is Tharimmune (THAR) Stock Up 113% Today?</a></li>



<li><a href="https://investorplace.com/2023/11/why-is-senti-biosciences-snti-stock-up-140-today/">Why Is Senti Biosciences (SNTI) Stock Up 140% Today?</a></li>



<li><a href="https://investorplace.com/2023/11/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-nov-7th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Tuesday</a></li>
</ul>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771234">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771244">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771242">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
		<div>
			<div></div>
						<div></div>
					</div>
	</div>The post <a href="https://investorplace.com/2023/11/why-is-ventyx-biosciences-vtyx-stock-down-76-today/">Why Is Ventyx Biosciences (VTYX) Stock Down 76% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Ventyx Biosciences (VTYX) Stock Down 76% Today?

Eccogene, a Shanghai-Boston biotech, out-licensed global rights (ex-China) for its novel small molecule GLP-1 agonist to AstraZeneca in a $2 billion blockbuster deal. Eccogene will receive $185 million upfront and up to $1.8 billion in milestones.

Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal

Senti Biosciences GAAP EPS of -$0.83 misses by $0.39, revenue of $0.04M misses by $0.66M

Senti Biosciences GAAP EPS of -$0.77 misses by $0.33

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Thursday!



Moving stocks are earnings reports, public offerings, insider buying and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Bone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/">BBLG</a>) stock is rocketing more than 44% alongside heavy pre-market trading.</li>



<li>BioVie (NASDAQ:<a href="https://investorplace.com/stock-quotes/bivi-stock-quote/">BIVI</a>) shares are soaring over 19% without any clear news this morning.</li>



<li>Heart Test Laboratories (NASDAQ:<a href="https://investorplace.com/stock-quotes/hscs-stock-quote/">HSCS</a>) stock is surging more than 17% with strong early morning trading.</li>



<li>Yoshitsu (NASDAQ:<a href="https://investorplace.com/stock-quotes/tklf-stock-quote/">TKLF</a>) shares are gaining close to 16% despite any apparent news this morning.</li>



<li>Flora Growth (NASDAQ:<a href="https://investorplace.com/stock-quotes/flgc-stock-quote/">FLGC</a>) stock is rising over 15% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317871899&amp;type=PDF&amp;symbol=FLGC&amp;cdn=5882e28b5f1d979fb6e3d46dd126c4e3&amp;companyName=Flora+Growth+Corp.&amp;formType=4&amp;formDescription=Statement+of+changes+in+beneficial+ownership+of+securities&amp;dateFiled=2023-11-15">alongside insider buying</a>.</li>



<li>Senti Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/snti-stock-quote/">SNTI</a>) shares are increasing more than 13% with its <a href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-snti/senti-biosciences/news/senti-biosciences-third-quarter-2023-earnings-eps-beats-expe">latest earnings release</a>.</li>



<li>Esports Entertainment (NASDAQ:<a href="https://investorplace.com/stock-quotes/gmbl-stock-quote/">GMBL</a>) stock is climbing over 13% with heavy early morning trading.</li>



<li>Acutus Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/afib-stock-quote/">AFIB</a>) shares are jumping more than 13% with strong trading today.</li>



<li>Isun (NASDAQ:<a href="https://investorplace.com/stock-quotes/isun-stock-quote/">ISUN</a>) stock is heading 13% higher with its <a href="https://www.nasdaq.com/press-release/isun-inc.-reports-third-quarter-2023-results-2023-11-14">most recent earnings release</a>.</li>



<li>Soligenix (NASDAQ:<a href="https://investorplace.com/stock-quotes/sngx-stock-quote/">SNGX</a>) shares are up over 12% this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Volcon (NASDAQ:<a href="https://investorplace.com/stock-quotes/vlcn-stock-quote/">VLCN</a>) stock is crashing more than 46% as a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317850450&amp;type=PDF&amp;symbol=VLCN&amp;cdn=001b639a9f2126eaa0bf523d5e221ead&amp;companyName=Volcon+Inc.&amp;formType=S-1%2FA&amp;formDescription=%5BAmend%5D+General+form+for+registration+of+securities+under+the+Securities+Act+of+1933&amp;dateFiled=2023-11-08">public offering goes into effect</a>. </li>



<li>Augmedix (NASDAQ:<a href="https://investorplace.com/stock-quotes/augx-stock-quote/">AUGX</a>) shares are diving over 27% after <a href="https://www.nasdaq.com/press-release/augmedix-announces-pricing-of-upsized-public-offering-of-6250000-shares-of-common">pricing a public offering</a>.</li>



<li>Kubient (NASDAQ:<a href="https://investorplace.com/stock-quotes/kbnt-stock-quote/">KBNT</a>) stock is plummeting more than 17% <a href="https://investorplace.com/2023/11/why-is-kubient-kbnt-stock-down-14-today/">as its delisting approaches</a>.</li>



<li>Velo3D (NYSE:<a href="https://investorplace.com/stock-quotes/vld-stock-quote/">VLD</a>) shares are taking an over 15% beating after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317871328&amp;type=PDF&amp;symbol=VLD&amp;cdn=8f1f75ec001d1505c7491375cf77935b&amp;companyName=Velo3D+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2023-11-15">adjusting its Q3 earnings report</a>.</li>



<li>Alpine 4 (NASDAQ:<a href="https://investorplace.com/stock-quotes/alpp-stock-quote/">ALPP</a>) stock is tumbling more than 14% on Thursday morning.</li>



<li>Gaucho Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/vino-stock-quote/">VINO</a>) shares are sliding over 13% this morning.</li>



<li>Palisade Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/pali-stock-quote/">PALI</a>) stock is decreasing more than 13% today.</li>



<li>Siyata Mobile (NASDAQ:<a href="https://investorplace.com/stock-quotes/syta-stock-quote/">SYTA</a>) shares are falling over 12% after <a href="https://za.investing.com/news/siyata-mobile-earnings-missed-by-100-revenue-fell-short-of-estimates-2934605">missing estimates in Q3</a>. </li>



<li>Chemomab Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmmb-stock-quote/">CMMB</a>) stock is slipping more than 12% as it comes off a recent rally.</li>



<li>Sadot (NASDAQ:<a href="https://investorplace.com/stock-quotes/sdot-stock-quote/">SDOT</a>) shares closed out our pre-market stock movers down over 12% after <a href="https://finance.yahoo.com/news/sadot-group-inc-reports-third-213000334.html">missing EPS estimates in Q3</a>.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771243">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
		<div>
			<div></div>
						<div></div>
					</div>
	</div>The post <a href="https://investorplace.com/2023/11/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-nov-16th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday